pp-052 Tablets
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
Comments
For acute and chronic pain (specific sub-indications not publicly disclosed),
Phase 2 development.
a non-opioid pain therapy, implying no engagement with classical opioid receptors and a differentiated mechanism intended to avoid opioid-related risks.
Route / form: TBC, most consistent with an oral solid dosage form (likely tablet or capsule).
Differentiation: Non-opioid mechanism aimed at providing effective pain relief without the safety risks of opioids, including dependence, abuse potential, respiratory depression, or long-term opioid toxicity.
Manufacturer #18873
A privately-held, mid-size biopharma firm focused on developing and marketing therapies for ADHD, pain, addiction and CNS disorders. It combines proprietary drug-delivery technology with global development and licensing efforts to deliver patient-friendly medications worldwide.
Manufacturer usually replies in 45 days